- Home
- PCRX vs ARCT Comparison
PCRX vs ARCT Comparison
Compare PCRX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- ARCT
- Stock Information
- Founded
- PCRX 2006
- ARCT 2013
- Country
- PCRX United States
- ARCT United States
- Employees
- PCRX N/A
- ARCT N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- PCRX Health Care
- ARCT Health Care
- Exchange
- PCRX Nasdaq
- ARCT Nasdaq
- Market Cap
- PCRX 1.2B
- ARCT 320.8M
- IPO Year
- PCRX 2011
- ARCT N/A
- Fundamental
- Price
- PCRX $26.51
- ARCT $18.09
- Analyst Decision
- PCRX Buy
- ARCT Strong Buy
- Analyst Count
- PCRX 6
- ARCT 10
- Target Price
- PCRX $30.00
- ARCT $50.88
- AVG Volume (30 Days)
- PCRX 605.6K
- ARCT 499.7K
- Earning Date
- PCRX 11-05-2025
- ARCT 11-06-2025
- Dividend Yield
- PCRX N/A
- ARCT N/A
- EPS Growth
- PCRX N/A
- ARCT N/A
- EPS
- PCRX N/A
- ARCT N/A
- Revenue
- PCRX $705,848,000.00
- ARCT $122,122,000.00
- Revenue This Year
- PCRX $7.36
- ARCT N/A
- Revenue Next Year
- PCRX $10.07
- ARCT $28.92
- P/E Ratio
- PCRX N/A
- ARCT N/A
- Revenue Growth
- PCRX 2.25
- ARCT N/A
- 52 Week Low
- PCRX $13.04
- ARCT $8.04
- 52 Week High
- PCRX $27.64
- ARCT $25.88
- Technical
- Relative Strength Index (RSI)
- PCRX 56.74
- ARCT 53.17
- Support Level
- PCRX $26.22
- ARCT N/A
- Resistance Level
- PCRX $27.50
- ARCT $18.69
- Average True Range (ATR)
- PCRX 0.93
- ARCT 1.00
- MACD
- PCRX -0.09
- ARCT -0.75
- Stochastic Oscillator
- PCRX 43.78
- ARCT 92.77
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.